Effects of Ruxolitinib Treatment on Metabolic and Nutritional Parameters in Patients With Myelofibrosis From COMFORT-I

Clinical Lymphoma, Myeloma and Leukemia- United States

doi 10.1016/j.clml.2014.12.008

Full Text

Abstract

Available in

Categories

Cancer Research

Date

April 1, 2015

Authors

Srdan Verstovsek

John O. Mascarenhas

Publisher

Elsevier BV

Related search

Ruxolitinib as an Emerging Treatment in Myelofibrosis

Blood and Lymphatic Cancer: Targets and Therapy

English

Definition and Management of Ruxolitinib Treatment Failure in Myelofibrosis

Blood Cancer Journal

English

Safety and Efficacy of Ruxolitinib in Myelofibrosis Patients Without Splenomegaly

British Journal of Haematology

English

Ruxolitinib for Myelofibrosis–An Update of Its Clinical Effects

Clinical Lymphoma, Myeloma and Leukemia

Cancer Research

English

Efficacy of Ruxolitinib for Myelofibrosis

Expert Opinion on Pharmacotherapy

English

U.S. Food and Drug Administration Approval: Ruxolitinib for the Treatment of Patients With Intermediate and High-Risk Myelofibrosis

Clinical Cancer Research

Cancer Research

English

Sustained-Release Ruxolitinib: Findings From a Phase 1 Study in Healthy Subjects and a Phase 2 Study in Patients With Myelofibrosis

Hematological Oncology

Cancer Research

English

Cost-Effectiveness of Ruxolitinib vs Best Available Therapy in the Treatment of Myelofibrosis in Spain

Journal of Health Economics and Outcomes Research

English

JAK Inhibition With Ruxolitinib Versus Best Available Therapy for Myelofibrosis

New England Journal of Medicine

English